Abstract
RNA interference (RNAi) is a potent and specific mechanism for eliminating the mRNA of specific genes. This gene silencing mechanism occurs naturally and is highly conserved from plants to human cells, holding promise for functional genomics and for revolutionizing medicine due to its unlimited potential to treat genetic, epigenetic, and infectious disease. However, efforts to unleash the enormous potential of RNAi have met with significant challenges. Delivery is problematic because short interfering RNAs (siRNA) are negatively charged polymers that inefficiently enter cells and undergo rapid enzymatic degradation in vivo. In addition, the synthesis of siRNAs is expensive for long-term research and therapeutic applications. Recently, we have shown that nonpathogenic bacteria can be engineered to activate RNAi in mammalian cells (TransKingdom RNA interference; tkRNAi). This new approach offers several advantages and has significant implications. First, this method allows the establishment of a long-term stable gene silencing system in the laboratory against genes of interests in vitro and in vivo, and enables high-throughput functional genomics screening in mammalian systems. RNAi libraries can be constructed, stored, reproduced, amplified, and used with the help of E. coli as currently done with gene cloning. Second, this technology provides a clinically compatible way to achieve RNAi for therapeutic applications due to the proven clinical safety of nonpathogenic bacteria as a gene carrier. tkRNAi also eliminates the siRNA manufacture issue, and may circumvent or mitigate host interferon-like responses since siRNA is produced intracellularly.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsSpringer Nature is developing a new tool to find and evaluate Protocols. Learn more
References
Barik, S. (2005) Silence of the transcripts: RNA interference in medicine. J Mol Med 83, 764–773.
Cheng, J. C., Moore, T. B., and Sakamoto, K. M. (2003) RNA interference and human disease. Mol Genet Metab 80, 121–128.
Grunweller, A. and Hartmann, R. K. (2005) RNA interference as a gene-specific approach for molecular medicine. Curr Med Chem 12, 3143–3161.
Hannon, G. J. and Conklin, D. S. (2004) RNA interference by short hairpin RNAs expressed in vertebrate cells. Methods Mol Biol 257, 255–266.
Provost, P., Dishart, D., Doucet, J., Frendewey, D., Samuelsson, B., and Radmark, O. (2002) Ribonuclease activity and RNA binding of recombinant human Dicer. EMBO J 21, 5864–5874.
Tijsterman, M. and Plasterk, R. H. (2004) Dicers at RISC; the mechanism of RNAi. Cell 117, 1–3.
Gregory, R. I., Chendrimada, T. P., Cooch, N., and Shiekhattar, R. (2005) Human RISC couples microRNA biogenesis and posttranscriptional gene silencing. Cell 123, 631–640.
Hammond, S. M., Bernstein, E., Beach, D., and Hannon, G. J. (2000) An RNA-directed nuclease mediates post-transcriptional gene silencing in Drosophila cells. Nature 404, 293–296.
Li, C. X., Parker, A., Menocal, E., Xiang, S., Borodyansky, L., and Fruehauf, J. H. (2006) Delivery of RNA interference. Cell Cycle 5, 2103–2109.
Shankar, P., Manjunath, N., and Lieberman, J. (2005) The prospect of silencing disease using RNA interference. JAMA 293, 1367–1373.
Xiang, S., Fruehauf, J., and Li, C. J. (2006) Short hairpin RNA-expressing bacteria elicit RNA interference in mammals. Nat Biotechnol 24, 697–702.
Isberg, R. R., Voorhis, D. L., and Falkow, S. (1987) Identification of invasin: a protein that allows enteric bacteria to penetrate cultured mammalian cells. Cell 50, 769–778.
Young, V. B., Falkow, S., and Schoolnik, G. K. (1992) The invasin protein of Yersinia enterocolitica. : internalization of invasin-bearing bacteria by eukaryotic cells is associated with reorganization of the cytoskeleton J Cell Biol 116, 197–207.
Grillot-Courvalin, C., Goussard, S., Huetz, F., Ojcius, D. M., and Courvalin, P. (1998) Functional gene transfer from intracellular bacteria to mammalian cells. Nat Biotechnol 16, 862–866.
Mathew, E., Hardee, G. E., Bennett, C. F., and Lee, K. D. (2003) Cytosolic delivery of antisense oligonucleotides by listeriolysin O-containing liposomes. Gene Ther 10, 1105–1115.
de Fougerolles, A., Vornlocher, H. P., Maraganore, J., and Lieberman, J. (2007) Interfering with disease: a progress report on siRNA-based therapeutics. Nat Rev Drug Discov 6, 443–453.
Gilmore, I. R., Fox, S. P., Hollins, A. J., and Akhtar, S. (2006) Delivery strategies for siRNA-mediated gene silencing. Curr Drug Deliv 3, 147–145.
Kolida, S., Saulnier, D. M., and Gibson, G. R. (2006) Gastrointestinal microflora: probiotics. Adv Appl Microbiol 59, 187–219.
Snelling, A. M. (2005) Effects of probiotics on the gastrointestinal tract. Curr Opin Infect Dis 18, 420–426.
Daudel, D., Weidinger, G., and Spreng, S. (2007) Use of attenuated bacteria as delivery vectors for DNA vaccines. Expert Rev Vaccines 6, 97–110.
Kruis, W., Fric, P., Pokrotnieks, J., Lukas, M., Fixa, B., Kascak, M., Kamm, M. A., Weismueller, J., Beglinger, C., Stolte, M., Wolff, C., and Schulze, J. (2004) Maintaining remission of ulcerative colitis with the probiotic Escherichia coli. Nissle 1917 is as effective as with standard mesalazine Gut 53, 1617–1623.
Acknowledgements
We thank Dr. J. T. LaMont for advice and discussions, and C. Griillot-Courvalin of the Pasteur Institute, Paris, France for providing the sequences for Inv and Hly (pGB2Ω) and also for helpful discussions.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2009 Humana Press, a part of Springer Science+Business Media, LLC
About this protocol
Cite this protocol
Xiang , S. et al. (2009). In Vitro and In Vivo Gene Silencing by TransKingdom RNAi (tkRNAi). In: Sioud, M. (eds) siRNA and miRNA Gene Silencing. Methods in Molecular Biology, vol 487. Humana Press. https://doi.org/10.1007/978-1-60327-547-7_7
Download citation
DOI: https://doi.org/10.1007/978-1-60327-547-7_7
Published:
Publisher Name: Humana Press
Print ISBN: 978-1-60327-546-0
Online ISBN: 978-1-60327-547-7
eBook Packages: Springer Protocols